Form 4: Pacira CMO Sells Shares for Tax Obligations

Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, disposed of 6,168 shares of common stock to cover tax withholding obligations.

Summary

• Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, Inc. (PCRX), reported a transaction involving the disposition of shares.
• The transaction, dated January 30, 2026, involved 6,168 shares of common stock.
• These shares were withheld by the issuer to cover tax withholding obligations upon the vesting of a restricted stock unit award.
• The shares were disposed of at a price of $20.54 per share.
• Following this transaction, Mr. Slonin directly beneficially owns 172,355.175 shares of Pacira BioSciences common stock.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, as it reflects the vesting of equity compensation, indicating continued executive alignment, despite the necessary tax-related share disposition.

Positives

• The transaction represents the vesting of a restricted stock unit award, indicating continued executive compensation and alignment with shareholder interests.
• It is a non-discretionary sale for tax purposes, not a voluntary divestment of shares.

Negatives

• The disposition of 6,168 shares, even for tax purposes, results in a slight reduction in the Chief Medical Officer's direct beneficial ownership.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future outlook.

Industry Context

StockSavvy.ai notes that Form 4 filings are standard disclosures of insider transactions, providing transparency into executive and director stock ownership changes. This specific transaction is a common occurrence related to equity compensation vesting and tax obligations, typical across various industries.

Comparison to Industry Standards

• This is a routine Form 4 filing for a tax-related disposition of shares upon restricted stock unit (RSU) vesting. Such transactions are standard practice for executives receiving equity compensation across all industries, including biotechnology and pharmaceuticals, and do not indicate any unique company-specific issues or performance relative to peers.

Related Party Transactions

• The transaction involves the disposition of shares by an officer to the issuer to cover tax withholding obligations related to equity compensation, which is a standard related-party interaction in the context of executive compensation.

Stakeholder Impact

• Shareholders: The transaction is a routine part of executive compensation and does not indicate a change in company fundamentals or management's confidence. The slight reduction in direct ownership is offset by the underlying RSU vesting.
• Employees: Reinforces the company's equity compensation structure as a mechanism for rewarding and retaining key personnel.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by a Chief Medical Officer to cover tax obligations upon the vesting of restricted stock units. Such transactions are common and do not typically signal a change in management's confidence or the company's fundamentals, thus warranting a 'hold' recommendation based solely on this filing.

Keywords

Pacira BioSciences, PCRX, Jonathan Slonin, Chief Medical Officer, Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Unit, Equity Compensation